ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för rimonabant. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

29 träffar

Bibliografisk träff 2020-09-03

Acute rimonabant treatment promotes protein synthesis in C2C12 myotubes through a CB1-independent mechanism.

Le Bacquer O, Lanchais K, Combe K, Van Den Berghe L, Walrand S.

J Cell Physiol · research support, non-u.s. gov't; journal article · DOI 10.1002/jcp.30034

Bibliografisk träff 2020-08-24

High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain.

Wargent ET, Kepczynska M, Zaibi MS, Hislop DC, Arch JRS, Stocker CJ, Stocker CJ.

PeerJ · research-article; journal article · DOI 10.7717/peerj.9811

Bibliografisk träff 2020-08-08

Microstructure analysis of the effects of the cannabinoid agents HU-210 and rimonabant in rats licking for sucrose.

D'Aquila PS.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2020.173468

Bibliografisk träff 2020-08-06

Possible Role of Adipose Tissue and the Endocannabinoid System in Coronavirus Disease 2019 Pathogenesis: Can Rimonabant Return?

Briand-Mésange F, Trudel S, Salles J, Ausseil J, Salles JP, Chap H.

Obesity (Silver Spring) · comment; research-article; journal article · DOI 10.1002/oby.22916

Bibliografisk träff 2020-06-04

Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.

Murphy T, Le Foll B.

Biomolecules · review-article; review; journal article · DOI 10.3390/biom10060855

Bibliografisk träff 2020-05-15

Behavioral assessment of rimonabant under acute and chronic conditions.

Ettaro R, Laudermilk L, Clark SD, Maitra R.

Behav Brain Res · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.bbr.2020.112697

Bibliografisk träff 2020-02-25

Rimonabant suppresses RNA transcription of hepatitis B virus by inhibiting hepatocyte nuclear factor 4α.

Sato A, Ono C, Tamura T, Mori H, Izumi T, Torii S, Fauzyah Y, Yamamoto T, Morioka Y, Okuzaki D, Fukuhara T, Matsuura Y.

Microbiol Immunol · journal article · DOI 10.1111/1348-0421.12777

Bibliografisk träff 2020-02-18

CB1 Receptor-Dependent and Independent Induction of Lipolysis in Primary Rat Adipocytes by the Inverse Agonist Rimonabant (SR141716A).

Müller GA, Herling AW, Wied S, Müller TD.

Molecules · research-article; journal article · DOI 10.3390/molecules25040896

Bibliografisk träff 2020-01-02

CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced bone metabolism disorder and destruction in rats.

Dou ZJ, Gao XL, Jia YL, Chen J, Yang JJ, Chen Y, Wu SJ, Liu T, Wang MT, Yang C, Zhang N, Wang B.

Sleep Breath · research-article; journal article · DOI 10.1007/s11325-019-02009-9

Bibliografisk träff 2020-01-01

Involvement of cannabinoid type 1 receptor in fasting-induced analgesia.

Lee JY, Lee GJ, Nakamura A, Lee PR, Kim Y, Won CH, Furue H, Oh SB.

Mol Pain · research support, non-u.s. gov't; research-article; journal article · DOI 10.1177/1744806920969476

Bibliografisk träff 2019-08-01

Analysis of Direct Effects of the CB1 Receptor Antagonist Rimonabant on Fatty Acid Oxidation and Glycogenolysis in Liver and Muscle Cells in vitro.

Müller GA, Wied S, Herling AW.

Biochemistry (Mosc) · journal article · DOI 10.1134/s000629791908011x

Bibliografisk träff 2019-04-01

Cannabinoid CB<sub>1</sub> Receptor Antagonist Rimonabant Decreases Levels of Markers of Organ Dysfunction and Alters Vascular Reactivity in Aortic Vessels in Late Sepsis in Rats.

Leite-Avalca MCG, Staats FT, Verona D, de Souza P, Almeida MC, Silva-Santos JE, Zampronio AR.

Inflammation · journal article · DOI 10.1007/s10753-018-0919-z

Bibliografisk träff 2019-01-01

Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target.

Zhang B, Li J, Yang X, Wu L, Zhang J, Yang Y, Zhao Y, Zhang L, Yang X, Yang X, Cheng X, Liu Z, Jiang B, Jiang H, Guddat LW, Yang H, Rao Z.

Cell · research support, non-u.s. gov't; journal article · DOI 10.1016/j.cell.2019.01.003

Bibliografisk träff 2018-09-25

Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.

Tai S, Vasiljevik T, Sherwood AM, Eddington S, Wilson CD, Prisinzano TE, Fantegrossi WE.

Drug Alcohol Depend · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.drugalcdep.2018.08.011

Bibliografisk träff 2018-07-19

Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant.

Ravula A, Chandasana H, Setlow B, Febo M, Bruijnzeel AW, Derendorf H.

J Pharm Biomed Anal · research-article; journal article · DOI 10.1016/j.jpba.2018.07.004

Bibliografisk träff 2018-06-19

Computational investigation on the binding modes of Rimonabant analogs with CB1 and CB2.

Liu C, Yuan C, Wu P, Zhu C, Fang H, Wang L, Fu W.

Chem Biol Drug Des · research support, non-u.s. gov't; journal article · DOI 10.1111/cbdd.13337

Bibliografisk träff 2018-05-01

Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα<sub>i/o</sub> protein inhibitor.

Porcu A, Melis M, Turecek R, Ullrich C, Mocci I, Bettler B, Gessa GL, Castelli MP.

Neuropharmacology · research support, non-u.s. gov't; journal article · DOI 10.1016/j.neuropharm.2018.01.024

Bibliografisk träff 2017-04-21

Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation.

Robinson JD, Cinciripini PM, Karam-Hage M, Aubin HJ, Dale LC, Niaura R, Anthenelli RM, STRATUS Group.

Addict Biol · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1111/adb.12508

Bibliografisk träff 2012-04-01

The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors.

Baur R, Gertsch J, Sigel E.

Br J Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/j.1476-5381.2011.01405.x

Bibliografisk träff 2011-12-19

Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.

Craft RM, Wakley AA, Tsutsui KT, Laggart JD.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.111.188540

Bibliografisk träff 2011-07-11

CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).

Raffa RB, Ward SJ.

J Clin Pharm Ther · review; journal article · DOI 10.1111/j.1365-2710.2011.01284.x

Bibliografisk träff 2010-08-06

The identification of rimonabant polymorphs, sibutramine and analogues of both in counterfeit Acomplia bought on the internet.

Venhuis BJ, Vredenbregt MV, Kaun N, Maurin JK, Fijałek Z, de Kaste D.

J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2010.07.043

Bibliografisk träff 2010-01-08

Rimonabant (SR141716) induces metabolism and acquisition of fertilizing ability in human sperm.

Aquila S, Guido C, Santoro A, Gazzerro P, Laezza C, Baffa MF, Andò S, Bifulco M.

Br J Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/j.1476-5381.2009.00570.x

Bibliografisk träff 2009-05-21

Involvement of hypothalamic peptides in the anorectic action of the CB receptor antagonist rimonabant (SR 141716).

Verty AN, Boon WM, Mallet PE, McGregor IS, Oldfield BJ.

Eur J Neurosci · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1111/j.1460-9568.2009.06750.x

Bibliografisk träff 2008-07-25

Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).

van Diepen H, Schlicker E, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol · review; journal article · DOI 10.1007/s00210-008-0327-2

Bibliografisk träff 2008-03-01

[Rimonabant (Acomplia)].

Duh D, Vanddevijver A.

J Pharm Belg · journal article

Bibliografisk träff 2008-01-01

[Correct prescription of Acomplia (rimonabant) is assured by knowledge].

Birgersson MO.

Lakartidningen · letter; comment

Bibliografisk träff 2006-08-24

SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice.

Wilson DM, Varvel SA, Harloe JP, Martin BR, Lichtman AH.

Pharmacol Biochem Behav · journal article; research support, n.i.h., extramural · DOI 10.1016/j.pbb.2006.07.018

Bibliografisk träff 2002-01-01

Rimonabant. SR 141716, SR 141716a.

Författaruppgift saknas

Drugs R D · review; journal article · DOI 10.2165/00126839-200203010-00016